U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937957) titled 'A Phase I Study to Investigate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of BR111 for Injection in Patients With Advanced Malignancies' on April 14.
Brief Summary: This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Malignancies
Intervention:
DRUG: BR111 for Injection
BR111-101 f...